Polaryx Therapeutics

Update in progress

PLYX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Polaryx Therapeutics, Inc. is a clinical‑stage biotechnology company developing disease‑modifying therapies for rare pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX‑100, a preclinical oral combination therapy; PLX‑200, a repurposed oral small molecule; PLX‑300, a preclinical oral combination therapy; and PLX‑400, a preclinical gene therapy candidate. Founded in 2014, it is based in Paramus, New Jersey.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive